PMID: 28323117
Source: Jastreboff et al., NEJM 2023 TRIUMPH-4 Phase 3 (68 weeks, 445 participants) Phase 2 Type 2 Diabetes Trial (36 weeks, 281 participants) In the type 2 diabetes population, weight loss was lower than in the obesity trial which is consistent with the pattern seen across all GLP-1 drugs
Vanessa Mack (Dean) , provides personalized treatment plans tailored to your unique goals
At Klinic in Salem, our streamlined approach, including insurance verification and prior authorization support, ensures you can easily access this transformative treatment
Most of these symptoms peak during the first two to four weeks after each dose escalation and fade over the subsequent four to eight weeks as receptor adaptation occurs
Diabetes - laying of the first stepping stone The GLP-1 journey is rooted in the long search to understand diabetes, a condition first recognised as a medical problem in Ancient Egypt